Demographic
| | |
Female, n (%)
|
57 (98)
|
29 (97)
|
Age, mean (SD), years*
|
60.3 (13.3)
|
61.1 (10.8)
|
Disease duration, mean (SD), years*
|
3.5 (5.8)
|
4.7 (6.6)
|
Clinical manifestation, n (%)
| | |
Ocular symptoms
|
39 (67)
|
18 (60)
|
Oral symptoms
|
53 (91)
|
21 (70)
|
Objectively assessed dryness
|
48 (83)
|
24 (80)
|
Anti-SSA positivity
|
43 (74)
|
24 (80)
|
Anti-SSB positivity
|
24 (41)
|
14 (48)
|
Lymphocytic sialadenitis with focus score ≥1
|
10 (17)
|
12 (40)
|
ESSDAI, mean score (SD)*
|
2.6 (4.9)
|
2.6 (4.2)
|
Treatment
| | |
Corticosteroid
|
1 (1.7)
|
1 (3)
|
Immunosuppressant
|
0 (0)
|
0 (0)
|